A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

• Status: Completed
• Trial end date: 2017-06-19
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Male or female between 21 and 75 years old

• Body Mass Index (BMI) of 25 or more

Exclusion Criteria:

• Chronic Liver disease other than NASH

• Uncontrolled diabetes

• Any major surgery within 6 weeks of screening

• Unable to self-administer under the skin injections

• Any bone trauma, fracture or bone surgery within 8 weeks of screening